Buprenorphine photo (IMAGE)

Oregon Health & Science University

Buprenorphine photo

Caption

Despite a record-setting number of overdose deaths nationwide in 2022, a new study from Oregon Health & Science University finds that only one in four adolescent residential treatment centers nationwide provides buprenorphine, a proven medication to treat opioid use disorder. ‘It’s hard to imagine getting adolescents with opioid use disorder off fentanyl without buprenorphine,’ says co-author Todd Korthuis, M.D., M.P.H., head of addiction medicine at OHSU.

Credit

Oregon Health & Science University

Usage Restrictions

OHSU offers select multimedia assets for use by news outlets. (Commercial use is prohibited without prior written consent.) When using these materials, please: Credit photo with “OHSU”. Photographer name, caption and usage restrictions are embedded in the image metadata. Do not alter the content/nature of the photo. Color correction and cropping are allowed. For more information, please contact OHSU Strategic Communications at news@ohsu.edu or 503-494-8231.

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.